BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Raman A, Coffey NJ, Sheng X, Wahba J, Seasock MJ, Ma Z, Beckerman P, Laczkó D, Palmer MB, Kopp JB, Kuo JJ, Pullen SS, Boustany-Kari CM, Linkermann A, Susztak K. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest 2021;131:e136329. [PMID: 34651582 DOI: 10.1172/JCI136329] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Pollak MR, Friedman DJ. APOL1-Associated Kidney Disease. Emery and Rimoin' s Principles and Practice of Medical Genetics and Genomics 2023. [DOI: 10.1016/b978-0-12-812534-2.00007-2] [Reference Citation Analysis]
2 Ma J, Liu Z, Zhou S, Chen M, Gao L, Zuo X, Zhang X, Zhang J, Zhu Q. Renal tubular in TCE-sensitization-induced immune kidney injury: Role of mitochondrial DNA in activating the cGAS-STING signaling pathway. International Immunopharmacology 2022;113:109432. [DOI: 10.1016/j.intimp.2022.109432] [Reference Citation Analysis]
3 Andrews M, Yoshida T, Henderson CM, Pflaum H, McGregor A, Lieberman JA, de Boer IH, Vaisar T, Himmelfarb J, Kestenbaum B, Chung JY, Hewitt SM, Santo BA, Ginley B, Sarder P, Rosenberg AZ, Murakami T, Kopp JB, Kuklenyik Z, Hoofnagle AN. Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury. PLoS One 2022;17:e0276649. [PMID: 36279295 DOI: 10.1371/journal.pone.0276649] [Reference Citation Analysis]
4 Yoshida T, Latt KZ, Rosenberg AZ, Shrivastav S, Heymann J, Halushka MK, Winkler CA, Kopp JB. Transcriptomic Analysis of Human Podocytes In Vitro: Effects of Differentiation and APOL1 Genotype. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.10.011] [Reference Citation Analysis]
5 Lassén E, Bouchareb R, Daehn IS. Podocyte as the link between sterile inflammation and diabetic kidney disease. Kidney Int 2022;102:688-90. [PMID: 36150759 DOI: 10.1016/j.kint.2022.07.015] [Reference Citation Analysis]
6 Liu T, Yang L, Mao H, Ma F, Wang Y, Li S, Li P, Zhan Y. Sirtuins as novel pharmacological targets in podocyte injury and related glomerular diseases. Biomed Pharmacother 2022;155:113620. [PMID: 36122519 DOI: 10.1016/j.biopha.2022.113620] [Reference Citation Analysis]
7 Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol 2022. [PMID: 36064794 DOI: 10.1038/s41581-022-00621-9] [Reference Citation Analysis]
8 Friedman DJ, Ma L, Freedman BI. Treatment potential in APOL1-associated nephropathy. Current Opinion in Nephrology & Hypertension 2022;31:442-8. [DOI: 10.1097/mnh.0000000000000816] [Reference Citation Analysis]
9 Zhang C, Liu N. Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer. Front Immunol 2022;13:920059. [DOI: 10.3389/fimmu.2022.920059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. Kidney Int 2022:S0085-2538(22)00436-7. [PMID: 35661785 DOI: 10.1016/j.kint.2022.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
11 Savedchuk S, Raslan R, Nystrom S, Sparks MA. Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease. Circ Res 2022;130:1618-41. [PMID: 35549373 DOI: 10.1161/CIRCRESAHA.122.320873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Doke T, Susztak K. The multifaceted role of kidney tubule mitochondrial dysfunction in kidney disease development. Trends Cell Biol 2022:S0962-8924(22)00084-8. [PMID: 35473814 DOI: 10.1016/j.tcb.2022.03.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Jin J, Zhou TJ, Ren GL, Cai L, Meng XM. Novel insights into NOD-like receptors in renal diseases. Acta Pharmacol Sin 2022. [PMID: 35365780 DOI: 10.1038/s41401-022-00886-7] [Reference Citation Analysis]
14 Guerini D. STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments. Cells 2022;11:1159. [PMID: 35406723 DOI: 10.3390/cells11071159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Bruggeman LA, Azhibekov T, O'toole JF. Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 Nephropathies. American Journal of Kidney Diseases 2022. [DOI: 10.1053/j.ajkd.2022.02.011] [Reference Citation Analysis]
16 Myakala K, Wang XX, Jones BA, Hirschey MD, Yang X, Rosenberg AZ, Ginley B, Sarder P, Brodsky L, Jang Y, Na CH, Qi Y, Zhang X, Guha U, Lewien P, Wu C, Bansal S, Ma J, Cheema A, Panov J, Levi M. NAD metabolism modulates mitochondrial function and inflammation and prevents progression of diabetic kidney disease.. [DOI: 10.1101/2021.12.05.471273] [Reference Citation Analysis]